Retirees Trust Our 5 Favorite Strong Buy Safe Monthly Pay High-Yield Dividend Stocks - 24/7 Wall St. S&P 5006,626.60 +0.25% Dow Jones46,625.30 +0.31% Nasdaq 10024,304.20 +0.28% Russell 20002,542.02 +0.19% FTSE 10010,105.40 +0.89% Nikkei 22554,025.50 +1.21% Investing Retirees Trust Our 5 Favorite Strong Buy Safe Monthly Pay High-Yield Dividend Stocks How to Add Us to Google News Sending You to Google News in 3 While many Baby Boomershave enjoyed a long bull market over the past 35 years, there is a point whe ...

Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab Accessibility StatementSkip Navigation HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug con ...

I like Agree Realty ( ADC ). I always did. I often see people comparing it to Realty Income ( O ). Why? Because of its monthly dividends, triple net lease model, and similar segment focus. But there's more toI'm Cash Flow Venue and I've been investing for years trying to build my dividend portfolio. I like dividends doing the work for me, but I also have a separate growth portfolio.I'm an M&A Advisor, which means that I advise people and businesses on selling (but sometimes buying) their businesses.I usuall ...

Core Insights - The analyst has over a decade of experience researching various industries, including commodities like oil, natural gas, gold, and copper, as well as technology companies such as Google and Nokia, and emerging market stocks [1] Group 1: Company Focus - The analyst has a particular interest in covering metals and mining stocks, while also being comfortable with other sectors like consumer discretionary/staples, REITs, and utilities [1] Group 2: Research Methodology - The analyst has transitioned from writing a personal blog to creating a value investing-focused YouTube channel, where extensive research on hundreds of companies has been conducted [1]

Group 1 - The company invests significant resources, including thousands of hours and over $100,000 annually, to identify profitable investment opportunities, resulting in over 500 five-star reviews from members [1] - The company has released its Top Picks for 2026, offering a limited-time access promotion with a 30-day money-back guarantee and a $100 anniversary discount [1] - The investment strategy is independent of other investors' actions, including those of leading REIT portfolio managers [1] Group 2 - Jussi Askola, the President of Leonberg Capital, leads the investment group High Yield Landlord, which focuses on REIT investing and provides real-time portfolio updates and buy/sell alerts [2] - The group offers three distinct portfolios: core, retirement, and international, along with a chat room for direct interaction with analysts [2]

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 Accessibility StatementSkip Navigation MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will present three preclini ...

Core Insights - CytomX Therapeutics announced positive Phase 1 expansion data for its EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) [1][2] - The company plans to engage with the FDA regarding the registrational path for Varseta-M, aiming to improve treatment options for late-line CRC patients [2][3] Patient Characteristics - The study enrolled 93 patients with late-line metastatic CRC, with 60 patients in the Phase 1 expansion dose range [7] - Patients had a median of 3 prior lines of therapy, with 96% previously treated with irinotecan, and 76% had liver metastases [7] Efficacy Data - Confirmed response rates were 32% at 10 mg/kg and 20% at 8.6 mg/kg, with estimated progression-free survival (PFS) of 7.1 months and 6.8 months respectively [6][11] - Disease control rates were 84% to 90% across the expansion doses [9] Safety Profile - The safety profile was consistent with earlier data, with most treatment-related adverse events being Grade 1 or 2 [10] - The most common treatment-related adverse event was diarrhea, with a Grade 3 rate of 10% at the optimized doses [12] Future Plans - CytomX aims to align with the FDA on a potential registrational study design for Varseta-M in advanced CRC in 2026 [16] - A Phase 1 study evaluating Varseta-M in combination with bevacizumab has been initiated, with a Phase 1b/2 study expected to start by the end of 2026 [16]

Core Viewpoint - The article discusses the investment landscape in the real estate sector, highlighting the performance and potential of various real estate investment trusts (REITs) and related securities [2]. Group 1: Company Insights - Hoya Capital Research & Index Innovations is affiliated with Hoya Capital Real Estate, which provides investment advisory services focused on publicly traded securities in the real estate industry [2]. - The commentary emphasizes that it is for informational and educational purposes only, and does not constitute investment advice [2]. Group 2: Market Commentary - The article notes that past performance is not indicative of future results, and it does not guarantee the accuracy of the information presented [3]. - It highlights the unique risks associated with investments in real estate companies and housing industry companies, as well as ETFs [2].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights on product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]

Market Overview - The market has been experiencing a downward trend recently, with concerns that the ongoing conflict with Iran may lead to a recession [1] Analyst Background - The analyst is a top 1% financial expert on TipRanks and has a focus on dividend investing in quality blue-chip stocks, BDCs, and REITs [2] - The analyst aims to assist lower and middle-class workers in building investment portfolios of high-quality, dividend-paying companies [2] Investment Position - The analyst holds a beneficial long position in the shares of ADC through stock ownership or derivatives [3]